Necrotizing and crescentic GN (NCGN) with a paucity of glomerular immunoglobulin deposits is associated with ANCA. The most common ANCA target antigens are myeloperoxidase (MPO) and proteinase 3. In a manner that requires activation of the alternative complement pathway, passive transfer of antibodies to mouse MPO (anti-MPO) induces a mouse model of ANCA NCGN that closely mimics human disease. Here, we confirm the importance of C5aR/CD88 in the mediation of anti-MPO-induced NCGN and report that C6 is not required. We further demonstrate that deficiency of C5a-like receptor (C5L2) has the reverse effect of C5aR/CD88 deficiency and results in more severe disease, indicating that C5aR/CD88 engagement enhances inflammation and C5L2 engagement suppresses inflammation. Oral administration of CCX168, a small molecule antagonist of human C5aR/CD88, ameliorated anti-MPO-induced NCGN in mice expressing human C5aR/CD88. These observations suggest that blockade of C5aR/CD88 might have therapeutic benefit in patients with ANCA-associated vasculitis and GN.
Necrotizing and crescentic GN (NCGN) and vasculitis are associated with ANCA. 1, 2 ANCAs are specific for myeloperoxidase (MPO) and proteinase 3 (PR3). 1 Experimental data indicate that the pathogenesis of ANCA-associated vasculitis (AAV) involves activation of neutrophils by ANCA. 1,2 Injection of anti-MPO antibodies into mice causes NCGN and vasculitis, closely mimicking human AAV. 3 Alternative complement pathway activation is pivotal in the pathogenesis of anti-MPO NCGN in mice. [4] [5] [6] The relevance of alternative complement pathway activation to human AAV is supported by immunohistochemical demonstration of alternative complement pathway components at sites of AAV 7, 8 and by correlation of plasma alternative complement pathway activation fragments with AAV disease activity. 9 The complement anaphylatoxin C5a is a potent inflammatory mediator. 10, 11 The alternative classic and lectin pathways converge at the activation of C5, releasing C5a and C5b. C5a is a powerful chemoattractant for neutrophils, and ligation by C5a of C5aR/CD88 activates neutrophils. Blockade of C5a or C5a receptor (C5aR/CD88) ameliorates anti-MPO NCGN in mice. 5, 6 ANCA-activated neutrophils activate the alternative complement pathway. 4, 6, 12 Neutrophil priming results in increased availability of ANCA antigens at the surface where they interact with ANCA to activate neutrophils. Human neutrophils activated by human ANCA release factors that activate the alternative complement pathway. 4, 6, 12 In turn, C5a primes neutrophils and increase ANCA antigen expression. 6, 12 Cleavage of C5 also releases C5b, which joins with C6 to initiate the membrane attack complex (MAC). 11 Here we confirm the importance of C5aR/CD88 in mediating anti-MPO NCGN and report that C6 is not required. We also demonstrate that deficiency of another receptor for C5a, C5L2 (C5a-like receptor 2), 10 results in more severe disease. This is in accord with earlier studies that have shown an antiinflammatory effect of C5L2 engagement. 10, 13, 14 Therapeutic implications were investigated using CCX168, an antagonist of human C5aR/CD88 that is undergoing phase 2 evaluation in patients with AAV (EU Clinical Trials Register ID: EUCTR2011-001222-15-GB). Oral administration of CCX168 to humanized mice with knocked-in human C5aR/ CD88 ameliorated anti-MPO NCGN. Figure 1A ) in all mice (n=7) with an average of 8.1% crescents ( Figure 1B ). B6 mice with knockedout C5aR/CD88 were protected (P= 0.0359), with only 1 of 6 mice developing 1% crescents ( Figure 1B ). In contrast, B6 mice with knockout of C5L2 (C5a-like receptor 2) had more severe disease (P=0.0035), with 18% crescents ( Figure  1B ). These observations support a proinflammatory function for C5aR/ CD88 and an anti-inflammatory inhibitory function for C5L2, as previously reported. 10, 13 C5 activation is required to induce anti-MPO NCGN. 5, 6 C5 activation generates C5a and C5b. C5a mediates inflammation by attracting and activating neutrophils, whereas C5b joins with C6 to initiate MAC assembly. 11 To investigate the pathogenic role of C6, NCGN induction by anti-MPO IgG in WT C3H/HeJ mice was compared with that in C6 (Figure 2A ). The hC5aR mice have a mixed genetic background of 129S6 and B6. The higher percentage of crescents in these mice compared with that in B6 mice is consistent with our observation that 129S6 mice are genetically predisposed to more severe disease and that crosses between 129S6 and B6 mice have intermediate severity. 15 Mouse Leukocytes with Knocked-In hC5aR/CD88 and Knocked-Out Mouse C5aR/CD88 Respond to an Antagonist of hC5aR/CD88 Flow cytometry demonstrated hC5aR but not mC5aR on hC5aR knock-in mice ( Figure 3A ). CCX168 markedly retarded chemotaxis of leukocytes from hC5aR mice (Figures 3B). Oral pretreatment of hC5aR mice with a single dose of CCX168 inhibited the exudation of peritoneal neutrophils in response to thioglycollate ( Figure 3C ) as well as transient depletion of blood neutrophils caused by intravenous C5a administration ( Figure 3 , E and F), thus documenting an inhibitory effect of CCX168 on leukocyte function in hC5aR mice.
RESULTS

C5aR
A Small Molecule Inhibitor of hC5aR/CD88 (CCX168) in Mice with hC5aR/CD88 Ameliorates Anti-MPO-Induced NCGN Oral CCX168, 30 mg/kg daily, reduced the severity of anti-MPO NCGN in hC5aR mice. Glomerular crescents were reduced from 30.4% to 3.3% with CCX168 (P,0.0001) (Figure 2A ). Urine hematuria, proteinuria, and leukocyturia were reduced in mice receiving CCX168, 30 mg/kg per day ( Figure 2B ).
The protection by CCX168 resulted in reduced crescents (P,0.001) ( Figure 2C ) and necrosis (P,0.001). In control mice versus CCX168-treated mice, there were more glomeruli with neutrophils (33.2% versus 12.0%; P=0.007) and more neutrophils per glomerulus (1.2 versus 0.2; P=0.003). The amelioration of anti-MPO NCGN by CCX168 was dose dependent ( Figure 2C ). Thus, an antagonist of human C5aR/CD88 effectively ameliorates anti-MPO induced NCGN in mice with hC5aR/ CD88.
DISCUSSION
Acute inflammatory lesions of AAV are extremely destructive and characterized histologically by influx or neutrophils, leukocytoclasia, and necrosis. 16 ,1 7 These lesions of AAV indicate that the pathogenic inflammatory mechanism involves intense recruitment and activation of leukocytes, especially neutrophils.
The complement system complements inflammation that has been initiated by many inflammatory stimuli. The alternative complement pathway is particularly effective at augmenting and sustaining acute inflammation because it has a self-fueling amplification loop. 11 Observations in human AAV and in experimental animal models of AAV support an important role for the alternative complement pathway. The lesions of AAV are characterized by a paucity of immunoglobulin and complement, especially compared with typical immune complex or anti-glomerular basement membrane-mediated GN and vasculitis; however, low-intensity deposition of complement is common, especially at focal sites of inflammation and necrosis. 7, 8 Xing et al. detected factor B, properdin, MAC, and C3d in glomeruli and small blood vessels with active AAV, which suggested alternative pathway activation. 7 Gigante et al. also detected complement components in AAV lesions and observed that the extent of lesional C3c correlated with poor renal Figure 1 . C5aR (CD88) deficiency ameliorates, C5L2 deficiency enhances and C6 deficiency has no effect on anti-MPO-induced GN. WT B6, C5L2 outcome. 8 In patients with AAV, Gou et al. reported increased plasma levels of C3a, C5a, soluble C5b-9, and Bb in patients with active disease but not remission. 9 The plasma Bb correlated with percentage of crescents. Thus, data from tissue specimens and plasma samples support a role for alternative complement pathway activation in AAV. Animal models that closely mimic human AAV are induced by circulating anti-MPO in mice. 3, 4 The alternative complement pathway is required for disease induction by anti-MPO. 4 Blockade of C5a or C5a receptor (C5aR/CD88) ameliorates anti-MPO-induced NCGN. 5, 6 Interruption of the C5 axis with anti-C5 effectively ameliorates disease not only when given before but also when given 1 day after injection of anti-MPO. 5 The current studies confirm the role of C5aR in mediating anti-MPO NCGN using C5aR-deficient mice as well as a small molecule antagonist of C5aR. Of note, mouse C5a is able to cross-react with human C5aR/ CD88.
Deficiency of C5L2 had the opposite effect of C5aR/CD88 deficiency, indicating that C5aR/CD88 engagement enhances inflammation whereas C5L2 engagement suppresses inflammation, which has been proposed before. 10, 13, 14 C5aR/CD88 is a G protein-coupled receptor, whereas C5L2 is structurally homologous but deficient in G protein coupling. 10 C5 activation generates not only C5a but also C5b, which complexes with C6 to initiate the membrane attack complex (MAC) (C5b-9d). 11 We examined the importance of the C6 in murine anti-MPO NCGN using C6-deficient mice Figure 2 . C5aR/CD88 small molecule antagonist CCX168 ameliorates anti-MPO-induced GN. Daily administration of 30 mg/kg CCX168, an orally active small molecule antagonist of human C5aR, markedly reduced the severity of anti-MPO-induced NCGN in hC5aR knock-in mice (7 days after anti-MPO injection). (A) Glomerular crescent formation induced by anti-MPO was reduced from 30.4% with vehicle alone to 3.3% with CCX168 (P,0.0001). (B) Urine hematuria, proteinuria, and leukocyturia were reduced in mice receiving CCX168 (dipstick scale, 0-4+). (C) Glomerular crescent and necrosis formation was reduced in animals receiving CCX168. Data were analyzed by MannWhitney t test; **P,0.01 and ***P,0.001. Data are presented as the median with SEM. BID, twice daily; QD, daily.
and observed no effect. This C6-deficient strain has been used effectively in other mouse models in which the C6 deficiency ameliorated MAC-mediated injury. [18] [19] [20] MAC may be present in lesions but is not required to induce injury.
The amelioration of anti-MPO NCGN in mice with humanized C5aR/ CD88 not only provides additional support for the important pathogenic role for complement activation in AAV but also supports the possibility that therapy directed at preventing or reducing complement activation might be beneficial in patients with AAV.
CONCISE METHODS
Mice
WT C57B6/6J (B6) and C3H/HeJ mice were obtained from The Jackson Laboratory (Bar Harbor, ME 
Humanization of Mice with Human C5aR
Standard homologous recombination techniques were used to create mice with the murine C5a receptor replaced with the human C5a receptor. These mice had a mixed genetic background of 129S6 and C57BL/6. In addition to standard confirmation by genotyping, the effectiveness of replacement of the mC5aR with the hC5aR was tested by determining leukocyte expression of mC5aR versus hC5aR on peripheral blood leukocytes by flow cytometry, and by measuring CCX168 suppression of human C5a-induced chemotaxis of thioglycollate-induced peritoneal leukocytes from mC5aR versus hC5aR mice. CCX168 was prepared by the Medicinal Chemistry Department at ChemoCentryx 21 and formulated in polyethylene glycol 400/ Solutol (70/30). Response to human C5a of hC5aR knock-in mouse leukocytes was tested in vitro using a previously described chemotaxis assay. 22 In brief, migration of cells from the upper to the lower ChemoTX chamber (NeuroProbe, Gaithersburg, MD) in response to different concentrations of human C5a was determined by adding CyQUANT solution (Invitrogen) to each lower chamber and measuring the intensity of fluorescence (Migration Signal) of the DNA-binding fluorescent CyQUANT after 120 minutes, which is a relative measure of cell numbers. In vitro, human C5aR responds equally well to murine C5a and human C5a (data not shown), which is in accord with previously reported results. 23 The cross-reactivity of CCX168 has been tested against a panel of over 20 chemotactic receptor (including CCR1-10, CXCR1-7, C5L2, C3aR, and ChemR23) and has at least four orders of magnitude less reactivity versus C5aR (data not shown). According to use of a previously described method, 24 the effect on in vivo chemotaxis of oral pretreatment 2 hours before intraperitoneal thioglycollate injection with vehicle or a single dose of 30 mg/kg of CCX168 on cell count in peritoneal lavage was measured 24 hours after intraperitoneal injection of thioglycollate. CCX168 effects on C5a-induced leukopenia was studied in hC5aR knock-in mice 1 hour after oral administration of CCX168 by comparing leukocyte counts in blood drawn 1 minute before and 1 minute after intravenous administration of C5a (20 mg/kg).
Preparation of Pathogenic Mouse Antimurine MPO IgG
Purification of native mouse MPO and immunization of MPO 2 /2 mice were performed as previously described. 2 Urine was tested by dipstick for hematuria, proteinuria, and leukocyturia (Roche Diagnostics Corp., Indianapolis, IN). Kidney specimens were fixed in 10% buffered formalin and prepared for light microscopy using hematoxylin-eosin and periodic acid-Schiff staining. Glomerular crescents and necrosis were calculated as percentage of glomeruli with crescents or necrosis by counting all glomeruli in cross-sections of both kidneys, which averaged approximately 80 per crosssection. To evaluate neutrophil infiltration, immunohistochemical staining was carried out on paraffin sections using a biotin-labeled rat monoclonal antimouse neutrophil antibody (Cedarlane Laboratories Ltd., Burlington, Ontario, Canada), with detection with peroxidase-conjugated streptavidin (BioGenex, San Ramon, CA) and a DAKO Liquid DAB-chromogen system (Dako, Carpinteria, CA). Results were expressed as the percentage of glomeruli with neutrophils and the number of neutrophils per glomerulus.
Statistical Analysis
All data are presented as mean 6 SD. The data were analyzed using a t test and one-way ANOVA with Bonferroni multiple comparison post-test. P,0.05 was considered to indicate a statistically significant difference. All analyses were done using SAS software (version 9.3; SAS Institute, Cary, NC). 
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